올릭스

226950KOSDAQ

48.0 / 100

Reference Date: 2026-09-08

Financial Score15.0 / 40

News Sentiment21.0 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 19.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Olix is a biopharmaceutical company specializing in developing therapeutic drugs for difficult-to-treat diseases using RNA interference (RNAi) platform technology. The company leverages its proprietary 'self-delivering asymmetric siRNA (cp-asiRNA)' technology to create drug candidates targeting metabolic diseases, obesity, and cardiovascular conditions. Through technology licensing agreements with global and domestic pharmaceutical companies, including a significant deal with Eli Lilly, Olix has established a strong market presence and revenue streams.

Number of Employees

76people

Average Salary

198.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

13.68Industry Average 1.200.0Point

11.4x industry avg (risky)

ROE

-18.68Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

15.97Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲45.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼33.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -56.5% (improving, 3yr)

Detailed News Sentiment

12 totalPositive 12Neutral 0Negative 0Average Sentiment Score 84.2

Positive
올릭스, CPS 84% 보통주 전환…166만주 15일 상장
올릭스의 CPS 전환청구를 통해 대규모 주식 발행이 이루어져 시장 관심이 증가하고 있다.
Positive
올릭스, CPS 대규모 일괄 보통주 전환…"수급 불확실성 대폭 완화"
올릭스의 대규모 보통주 전환으로 수급 불확실성이 크게 완화되어 긍정적인 시장 반응 예상.
Positive
올릭스, 탈모약 호주 임상 1b상 추적관찰 완료…연내 2a상 진입 목표
올릭스의 탈모 치료제 임상 1b상 성공적 완료로 안전성과 내약성이 입증되어 향후 2a상 진입 기대감 상승.

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 97,500Won52-week high 207,00052-week low 81,700

1-month return0.0Point

1m -19.55% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-09-01
Neutral전환주식의전환청구권행사 (전환우선주)2026-09-01
Neutral전환주식의전환청구권행사 (전환우선주)2026-08-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-28
Neutral투자판단관련주요경영사항 (Hansoh와의 공동연구 및 염기서열 이전 계약 체결)2026-08-21